Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610618-24-000156
Filing Date
2024-12-19
Accepted
2024-12-19 18:20:55
Documents
1
Period of Report
2024-12-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1734650448.html 4  
1 FORM 4 wk-form4_1734650448.xml 4 3857
  Complete submission text file 0001610618-24-000156.txt   5471
Mailing Address C/O HOLLIS-EDEN PHARMACEUTICALS 4435 EASTGATE MALL STE.400 SAN DIEGO CA 92121
Business Address
BURGESS DANIEL D (Reporting) CIK: 0001239650 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36912 | Film No.: 241564610

Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Issuer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)